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Abstract
Background: The incidence and mortality rates of gastric cancer (GC) rank in top five among all malignant tumors.
Chemokines and their receptor-signaling pathways reportedly play key roles in the metastasis of malignant tumor
cells. Receptor activator of nuclear factor κB ligand (RANKL) is a member of the tumor necrosis factor family, with
strong chemokine-like effects. Some studies have pointed out that the RANKL/RANK pathway is vital for the metastasis of cancer cells, but the specific mechanisms in GC remain poorly understood.
Results: This study reports original findings in cell culture models and in patients with GC. Flow cytometry and
western blotting analyses showed that RANK was expressed in BGC-823 and SGC-7901 cells in particular. Chemotaxis
experiments and wound healing assay suggested that RANKL spurred the migration of GC cells. This effect was offset
by osteoprotegerin (OPG), a decoy receptor for RANKL. RANKL contributed to the activation of human epidermal
growth factor receptor (HER) family pathways. The lipid raft core protein, caveolin 1 (Cav-1), interacted with both RANK
and human epidermal growth factor receptor-1(EGFR). Knockdown of Cav-1 blocked the activation of EGFR and cell
migration induced by RANKL. Moreover, RANK-positive GC patients who displayed higher levels of EGFR expression
had poor overall survival.
Conclusions: In summary, we confirmed that with the promotion of RANKL, RANK and EGFR can form complexes
with the lipid raft core protein Cav-1, which together promote GC cell migration. The formation of the RANK-Cav1-EGFR complex provides a novel mechanism for the metastasis of GC. These observations warrant confirmation in
independent studies, in vitro and in vivo. They also inform future drug target discovery research and innovation in the
treatment of GC progression.
Keywords: Gastric cancer, Metastasis, Cancer biology, EGFR, RANKL, Drug targets, Translational medical research
Background
A recent study reported that the incidence and mortality
rates of GC rank second among all malignant tumors [1].
The majority of patients miss the opportunity to be cured
by surgery. Less than 10% of them can live for more than
five years and the median survival time is less than 1 year
[2]. One of the major causes of the low survival rate is

*Correspondence: cmuliuyunpeng@hotmail.com; ypliu@cmu.edu.cn;
xiujuanqu@yahoo.com
1
Department of Medical Oncology, The First Hospital of China Medical
University, Shenyang 110001, China
Full list of author information is available at the end of the article

local infiltration and abdominal implant transfer due to
GC cell migration.
In recent years, chemokines and their receptor-signaling pathways have been reported to have major roles in
the metastasis of cancer cells [3]. RANKL is the ligand
of RANK, with a strong chemokine-like effect [4]. The
presence of RANKL/RANK pathway has been confirmed in malignant tumors of the respiratory, endocrine,
reproductive, and lymphatic systems [5–7]. The RANK/
RANKL pathway has also been demonstrated to be an
important regulator of mammary stem cells and mammary gland development [8]. In addition, it is vital for the
initiation, progression, and metastasis of breast cancer
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[9, 10]. Recently, GC sufferers with high levels of RANKL
expression have been confirmed to have shorter overall
survival [11].
The biological function, mechanism, and significance
of the epidermal growth factor receptor family have
been extensively reported. EGFR and HER2 are generally considered to be markers of poor prognosis in GC
sufferers [12, 13]. Studies have shown that RANK can
interact with EGFR to regulate osteoclast differentiation
and survival [14]. Furthermore, the interaction between
EGFR and RANK has been corroborated in vitro and in
animal models of metastasis. In addition, the RANK/
RANKL axis also has a crucial impact on the occurrence
of ErbB2-positive breast cancer [15]. Rodent experiments have shown that RANK can lead to breast cancer
progression and can induce early-stage tumor metastasis
in HER2-positive breast cancer models, by direct ligand
stimulation [16, 17]. According to our present research,
RANKL not only stimulated the migration of GC cells,
but also promoted EGFR activation, which could be
blocked by Cav-1 knockdown. The discovery of this
RANK-Cav-1-EGFR complex revealed a novel mechanism for the metastasis of GC.

Results
RANKL induced the migration of GC cells via RANK
and EGFR

We first verified the RANK expression in various GC
cells by western blot (Fig. 1a). After comparison, RANK
protein expression levels were highest in BGC-823 and
SGC-7901 GC cells. We then tested whether RANK was
expressed on the surface of these GC cells. Flow cytometry results showed RANK expression on the surface
of BGC-823 and SGC-7901 GC cells (Fig. 1b). Transwell experiments were then used to determine whether
RANKL could promote GC cell migration. The results
indicated that RANKL (1.0 μg/mL) promoted the migration of GC cells, compared to untreated cells. After the
addition of its inhibitor, OPG (10 μg/mL), RANKLinduced GC cell migration was significantly attenuated
(Fig. 1c). After being treated with the same reagent and
concentration as transwell, the wound healing experiments further confirm the phenomenon above (Fig. 1d).
These results suggested that RANKL stimulated the
migration of GC cells through RANK.
To investigate whether RANKL had an effect on the
HER family, we treated both GC cells with RANKL for
the indicated times and observed the level of phosphorylated EGFR. EGFR phosphorylation was obviously
up-regulated at 5 min in BGC-823 and 15 min in SGC7901. Other members of the HER family also showed
transient or sustained phosphorylation (Fig. 2a). Moreover, the downstream molecular changes induced by the
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RANKL-mediated activation of EGFR were offset by
transfection of siEGFR (Fig. 2b). Silencing EGFR also
partially reversed RANKL-induced GC cell migration
(Fig. 2c, d). This indicated that RANKL promoted the
migration of GC cells through EGFR and its downstream
signaling pathway.
The activation of EGFR by RANKL depended on Cav‑1

Numerous membrane receptors interact with each other
on the lipid raft platform. To determine the mechanism
whereby RANKL regulates EGFR, we examined Cav-1, a
key protein of lipid rafts. The results showed that phosphorylated Cav-1 was activated by RANKL in SGC-7901
cells after 45 min of treatment and in BGC-823 cells after
15 min of treatment (Fig. 3a). Silencing of the Cav-1 gene
inhibited RANKL-induced EGFR activation (Fig. 3b).
This result indicated that RANKL might induce GC cell
migration by Cav-1-mediated EGFR activation.
RANKL promoted GC cell migration through the formation
of a RANK‑Cav‑1‑EGFR complex

Since RANKL activated EGFR and Cav-1 and Cav-1
regulated EGFR activation, we explored the interaction
between these proteins. Our results showed that Cav-1
naturally bound to RANK and EGFR. When treated
with RANKL, the interaction of Cav-1, RANK, and
EGFR increased after 5 min in BGC-823 cells and after
15 min in SGC-7901 cells (Fig. 4a). Knockdown of Cav-1
inhibited the RANK-Cav-1-EGFR complex assembling
(Fig. 4b). Taken together, these findings indicated that
RANKL induced GC cell migration through the formation of a RANK-Cav-1-EGFR complex.
High levels of EGFR expression were associated with worse
overall survival in RANK‑positive GC sufferers

To clarify the impact of RANK and EGFR on disease
prognosis, we collected 68 primary GC specimens and
used immunohistochemistry to assess EGFR and RANK
expression. Immuno-staining confirmed high levels of
EGFR expression in 19 patients (27.9%) and high levels
of RANK expression in 28 patients (41.2%, Fig. 5a). We
grouped RANK-positive patients based on their level of
EGFR expression.
Table 1 shows the correlation between EGFR expression and clinic-pathological features in RANK high
expression group. The univariate analysis showed that
gender and age were not associated with EGFR expression. There existed a positive correlation between EGFR
expression and TNM staging and N staging. We get
the conclusion that the prognosis was significantly better in those with low EGFR expression sufferers than
in those with high EGFR expression sufferers (Fig. 5b).
This schematic diagram shows our research content very
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Fig. 1 RANKL promotes gastric cancer cell migration through RANK. a Western blot showed that RANK protein was expressed in various gastric
cancer cells. b The results of flow cytometry showed that there were two peaks of blue and red in gastric cancer cells, indicating that there was
a high expression of RANK on the surface of gastric cancer cells. c SGC-7901 and BGC-823 cells were treated with RANKL (1 μg/ml) for 24 h. The
transwell assay results showed that the number of cell migration increased significantly. When OPG (10 μg/ml) was added at the same time, the
effect of RANKL was cancelled out. d The wound healing assay (magnification, × 100) also confirmed that RANKL can promote gastric cancer
migration. Data are mean ± SD in three independent experiment. (**p < 0.01)

intuitively: After being stimulated by RANKL, the transmembrane proteins EGFR and RANK form a complex
with Cav-1 on the lipid raft platform, which further activates downstream signaling pathways and ultimately promotes gastric cancer migration (Fig. 5c).

Discussion
Numerous evidence supports RANK’s important
function in the development and progression of cancer. RANKL stimulates RANK and has effects on the

migration and invasion of cancer cells. Furthermore,
RANKL/RANK function as predictors of tumorigenesis
and prognosis in many solid tumors, including breast
cancer and GC [18–20]. RANKL and its receptor, RANK,
can be modulated by EGFR signaling [21]. However, the
precise molecular mechanisms by which these two pathways interact with each other to affect cancer cell migration remain unclear.
In the present study, flow cytometry and immunoblotting experiments demonstrated that RANK exists in
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Fig. 2 RANKL promotes migration of gastric cancer cells by activating EGFR pathway. a After treatment with RANKL at different time points, the HER
family members showed persistent or transient phosphorylation activation by western blot. b RANKL can up-regulate the levels of P-EGFR, P-AKT
and P-ERK. However, this effect can be counteracted by transfection of siEGFR. c, d The transwell assay and wound healing assay results showed
that the RANKL can up-regulate the number of cell migration increased significantly. Same as above, this effect can be counteracted by transfection
of siEGFR. Data are mean ± SD in three independent experiment. (**p < 0.01)
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Cav-1 siRNA. The results of these experiments demonstrated that EGFR activity was regulated by RANKL, in
a Cav-1-dependent manner. In particular, co-immunoprecipitation experiments revealed that Cav-1 naturally
bound with RANK and EGFR. Based on the present findings, we conclude that Cav-1 may make a major contribution to the relationship between RANKL/RANK and
the EGFR pathway, which are involved in regulating the
migration of GC cells. These data also provide new ideas
for explaining and avoiding resistance to EGFR tyrosine
kinase inhibitors.
While our study suggested new evidence regarding
the mechanisms of GC progression, several limitations
should be noted. The clinical study sample size was limited and therefore, future studies with larger sample
sizes and in independent populations are required to
confirm the findings presented here. To further confirm
that Cav-1 directly or indirectly interacts with RANK or
EGFR and to identify the functional domain of the binding site, genetic variants of RANK, EGFR, and Cav-1
should be employed. In addition, GST pull-down experiments could be used to advance this emerging body of
knowledge on GC cell migration and metastasis.
Fig. 3 The activation of EGFR by RANKL depends on the existence of
Cav-1. a The gastric cancer cells were treated with RANKL (1 μg/ml)
for the indicated times by Western blot, the level of p-Cav-1 increased
significantly, BGC-823 for 15 min and SGC-7901 for 45 min. b While
we knocked down of Cav-1 gene by using Cav-1 siRNAs for 72 h,
Cav-1 and P-Cav-1 decreased significantly, P-EGFR also decreased
significantly

all five GC cell lines, with the highest levels observed in
SGC-7901 and BGC-823 cells. Consistent with previous findings, RANK was located on the cell membrane.
Furthermore, we examined the effect of RANKL on cell
migration and verified that RANKL promoted the invading ability of GC cells. Meanwhile, the stimulation of cell
migration by RANKL could be inhibited by EGFR siRNA.
More importantly, by activating the EGFR signaling pathway, RANKL notably activated p-EGFR and the expression of its downstream protein, MAPK. Our data not
only showed that RANK promoted tumor cell invasion
through RANKL, but also suggested that there was crosstalk between the RANK/RANKL pathway and the EGFR
signaling pathway.
Another important result in this study was that
RANKL facilitated the phosphorylation of Cav-1, a key
component of lipid rafts, which regulate signal transduction at the cell surface [22]. To further explore the
molecular mechanisms of the interaction between
RANKL and EGFR in the regulation of GC invasion and
progression, we silenced Cav-1 protein function using a

Conclusions
The formation of RANK-Cav-1-EGFR complex provides a novel mechanism for the metastasis of GC. These
observations warrant further replication in independent
studies in vitro and in vivo. They also inform future drug
target discovery,immunity therapy and diagnostics innovation for GC progression in particular [23].
Materials and methods
Clinical study, participants, and research ethics

Samples of GC tissue were gathered from 68 sufferers who received Radical surgery at the First Hospital of
China Medical University (Shenyang, China) from March
2006 to October 2011. No one had ever received any
form of anti-tumor treatment. Clinical and pathological features were evaluated following medical charts and
pathological records. The Ethical Committee of the First
Hospital of China Medical University approved the study.
Reagents

RANKL and OPG were obtained from CytoLab/PeproTech Asia (Rocky Hill, NJ, USA). The Cav-1 siRNA was
obtained from Shanghai GenePharma Co. Ltd (Shanghai,
China). The EGFR siRNA and protein agarose beads were
purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Lipofectamine 2000 was purchased from
Invitrogen (Carlsbad, CA, USA).
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Fig. 4 RANKL promoted the formation of a RANK-Cav-1-EGFR complex. a The SGC-7901 and BGC-823 cells were treated with RANKL for the
indicated times. Whole cell lysates were immune-precipitated with anti-Cav-1 antibody. The interaction of CAV-1 with RANK and EGFR was
significantly enhanced providing by Western blot. b While silencing Cav-1 gene by using Cav-1 siRNAs for 72 h, and then treated with RANKL for
indicated time. The formation ability of Cav-1-RANK-EGFR complex decreased significantly. Input represents cell lysates that were not subjected to
immune-precipitation and IgG as an IP-control
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Fig. 5 The relationship between the expression of EGFR and RANK and prognosis. a The cases of simultaneous negative and positive expression of
EGFR and RANK. b The patients with double positive EGFR and RANK had the worst prognosis. c Schematic diagram of RANKL-mediated complex
formation leading to enhanced migration of GC cells

Table 1 RANK positive expression and clinicalpathological
characteristics of GC
Characteristics

Cases

EGFR
Low (%)

High (%)

15 (53.6)

9 (32.1)

3 (10.7)

1 (3.6)

11 (39.3)

5 (17.9)

> 60

7 (25)

5 (17.9)

I + II

7 (25)

0 (0)

p value

Cell culture

Five GC cells were purchased from the Cell Bank of the
Chinese Academy of Sciences (Shanghai, China). The
specific methods refer to our previous article [24].
Flow cytometry

Sex
Male
Female

0.495

Age (years)
≤ 60

0.590

Western blotting

pTNM stage
III

11 (39.3)

BGC-823 and SGC-7901 cells were sowed at 2.5 × 105
cells/well in six-well plates. RANK expression was
detected by flow cytometry according to a previously
described method [25].

0.022*

Western blotting was performed as previously described
[25, 26].

0.29

Immunoprecipitation assay

10 (35.7)

T stage
T1-2

2 (7.1)

T3-4

16 (57.1)

0 (0)
10 (35.7)

N stage
N0
N1-3

0 (0)
18 (64.3)

0 (0)
10 (35.7)

< 0.05*

Antibodies against EGFR and Cav-1, protein A-agarose
beads, and cell lysates were incubated for 6 h at room
temperature. The resulting complex was washed four
times with lysis buffer. The technical details of this procedure are described in our previous publication [27].
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Transwell migration assay

For each sample, 200 μl of pretreated cells in serum-free
RPMI 1640 medium (SGC-7901, 1 × 104 cells/well; BGC823, 3 × 104 cells/well; EGFR or Cav-1 gene knocked out)
was loaded into the upper well. The lower chambers supplemented with or without RANKL. The specific experimental methods refer to our previous article [24].
Wound healing assay

For detailed experimental methods, please refer to our
previous research [28].
Transfection with small interfering RNA

The cultured cells were transiently transfected by using
Lipo 2000 at the request of the instructions. The following siRNA sequences were used: siCav-1, 5′-AACCAG
AAGGGACACACAGUU-3′; EGFR, 5′-CUCCAGAGG
AUGUUCAAUATT-3′; and control, 5′-AATTCTCCG
AACGTGTCACGT-3′. After 48–72 h of transfection, the
cells were sub-cultured for further experiments.
Immunohistochemical experiments

GC tissues were formalin-fixed, paraffin-embedded, and
cut into 3 µm sections. The specific details of the immunehistochemical method have been described in our previous
report [27]. Briefly, the following antibodies were used for
immune-histochemical staining: an anti-RANK antibody
from R&D Systems (Minneapolis, MN, USA) and an antiEGFR antibody from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Two independent pathologists observed
and evaluated the stained tissue sections by microscopy
( × 20 and × 40 magnification). Five fields were randomly
selected from each section and scored based on the percentage of positive cells and the staining intensity of the
cells. Sections with 0–10, 10–25, 26–50, 51–75, or > 76%
of positively stained cells were recorded as 0, 1, 2, 3, and 4,
respectively. Scores > 2 were defined as high expression levels and scores of 0–2 were defined as low expression levels.
Statistical analysis

All experiments were performed on at least three independent occasions. Data were summarized and are
showed as the mean ± SD. Statistical comparisons were
performed using a Student’s t-test, with p < 0.05 considered
statistically significant. Statistical analysis was performed
using SPSS 24.0 software (SPSS, Inc., Chicago, IL, USA).
Abbreviations
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growth factor receptor-1; ERK: extracellular regulated kinase; FBS: fetal calf
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